Wang Jiali, Lin Yongda, Chen Xiutian, Liu Yiping, Zhou Tianbiao
Department of Nephrology, the Second Affiliated Hospital, Shantou University Medical College, Shantou, China.
Front Cell Dev Biol. 2022 Oct 4;10:910592. doi: 10.3389/fcell.2022.910592. eCollection 2022.
Chronic kidney disease (CKD) has a major impact on public health, which could progress to end-stage kidney disease (ESRD) and consume many medical resources. Currently, the treatment for CKD has many flaws, so more effective treatment tools are urgently required for CKD. Mesenchymal stem cells (MSCs) are primitive cells with self-renewal and proliferation capacity and differentiation potential. Extensive preclinical and clinical data has shown that cell-based therapies using MSCs can modulate immunity, inhibit inflammatory factors, and improve renal function in CKD, suggesting that MSCs have the potential to be a new, effective therapeutic tool for CKD. In this review, we will describe different kinds of MSCs and MSCs products for the treatment of CKD in experimental models and clinical trials, potential signaling pathways, therapeutic efficacy, and critical issues that need to be addressed before therapeutic application in humans.
慢性肾脏病(CKD)对公众健康有重大影响,它可能进展为终末期肾病(ESRD)并消耗大量医疗资源。目前,CKD的治疗存在诸多缺陷,因此迫切需要更有效的治疗手段。间充质干细胞(MSCs)是具有自我更新、增殖能力和分化潜能的原始细胞。大量临床前和临床数据表明,使用MSCs的细胞疗法可调节免疫、抑制炎症因子并改善CKD患者的肾功能,这表明MSCs有潜力成为治疗CKD的新型有效治疗手段。在本综述中,我们将描述用于治疗实验模型和临床试验中CKD的不同类型的MSCs及其产品、潜在信号通路、治疗效果以及在应用于人类治疗之前需要解决的关键问题。